3.3 Dyslipidemias, Apolipoproteins & Cardiac Risk Biomarkers

3.3 Dyslipidemias, Apolipoproteins & Cardiac Risk Biomarkers

[!NOTE] ASCP Exam Focus: Laboratory technologists must master: (1) the Fredrickson-Levy-Lee classification of hyperlipoproteinemias, matching each Roman numeral phenotype to its elevated particle, lipid elevations, molecular defect, standing plasma test appearance, and pathognomonic physical findings; (2) the hallmark features of Abetalipoproteinemia and Tangier disease; (3) the clinical value of Apo B-100 and Lipoprotein(a); and (4) the diagnostic applications and critical pre-analytical caveats of hs-CRP and natriuretic peptides (BNP vs. NT-proBNP).

---

The Fredrickson-Levy-Lee Classification of Hyperlipoproteinemias

Established in 1967 by Donald Fredrickson, Robert Levy, and Robert Lee and formally adopted by the World Health Organization (WHO), this classification categorizes hyperlipidemias into six discrete phenotypic patterns based on elevated lipoprotein fractions, electrophoretic migration, standing plasma appearance, and lipid profiles.

+-----------------------------------------------------------------------------------------------------------------------------+
|                                 Fredrickson-Levy-Lee Classification Master Table                                             |
+-----------------------------------------------------------------------------------------------------------------------------+
| Type | Elevated Particle(s)  | Primary Lipid Elevation | Standing Plasma (4°C)     | Primary Molecular Defect               |
+------+-----------------------+-------------------------+---------------------------+----------------------------------------+
| I    | Chylomicrons          | Triglycerides (extreme, | Creamy top layer;         | LPL deficiency or Apo C-II deficiency  |
|      |                       | >1000-5000 mg/dL)       | Clear infranatant         | (Autosomal recessive)                  |
+------+-----------------------+-------------------------+---------------------------+----------------------------------------+
| IIa  | LDL                   | Total Cholesterol       | Completely clear;         | LDL Receptor deficiency (*LDLR*),      |
|      |                       | (300-1000+ mg/dL)       | Often deep yellow/orange  | *APOB* mutation, or *PCSK9* gain       |
+------+-----------------------+-------------------------+---------------------------+----------------------------------------+
| IIb  | LDL and VLDL          | Total Cholesterol &     | Clear to slightly hazy;   | Hepatic overproduction of Apo B-100    |
|      |                       | Triglycerides           | No floating cream layer   | and delayed clearance (Polygenic)      |
+------+-----------------------+-------------------------+---------------------------+----------------------------------------+
| III  | IDL and Beta-VLDL     | Total Cholesterol &     | Turbid to hazy infranatant| Homozygous *APO-E2/E2* genotype;        |
|      | (VLDL Remnants)       | Triglycerides (~1:1)    | Occasional faint surface  | Defective remnant receptor binding     |
+------+-----------------------+-------------------------+---------------------------+----------------------------------------+
| IV   | VLDL                  | Triglycerides           | Uniformly turbid / milky; | Hepatic VLDL overproduction or         |
|      |                       | (200-800 mg/dL)         | NO floating cream layer   | impaired lipolysis (Autosomal dominant)|
+------+-----------------------+-------------------------+---------------------------+----------------------------------------+
| V    | Chylomicrons and VLDL | Triglycerides (extreme) | Creamy top layer;         | Severe polygenic defect / Apo C-II     |
|      |                       | & Total Cholesterol     | Turbid / milky infranatant| saturation combined with VLDL excess   |
+-----------------------------------------------------------------------------------------------------------------------------+

Detailed Phenotypic Breakdown

Type I: Familial Hyperchylomicronemia

• Molecular Defect: Autosomal recessive loss-of-function mutations in the Lipoprotein Lipase (LPL) gene (>80% of cases) or its obligate cofactor Apolipoprotein C-II (APOC2). Rarer causes include mutations in GPIHBP1, APOA5, or LMF1.
• Laboratory Profile: Massive hypertriglyceridemia (often 1500 to 5000+ mg/dL); Total Cholesterol is normal or mildly elevated. Overnight standing plasma displays a pathognomonic thick, creamy floating curd-like layer over a crystal clear infranatant.
• Clinical Presentation: Manifests in childhood or infancy. Characterized by recurrent, life-threatening acute pancreatitis (the primary cause of mortality), eruptive xanthomas (crops of small, 1–4 mm, yellowish papules on an erythematous base over the buttocks, back, and extensor surfaces of elbows/knees), lipemia retinalis (creamy pink/white discoloration of retinal vessels on fundoscopy when TG > 2000 mg/dL), and hepatosplenomegaly.
• Cardiovascular Risk: NOT associated with premature coronary artery disease. Chylomicrons (80–1000 nm) are physically too large to penetrate the arterial endothelial barrier into the subendothelial space.
• Management: Extreme restriction of dietary fat (<10% to 15% of total daily caloric intake) and supplementation with medium-chain triglycerides (MCTs, which are absorbed directly into the portal vein without chylomicron packaging).

Type IIa: Familial Hypercholesterolemia (FH)

• Molecular Defect: Autosomal dominant inheritance of mutations in the LDL Receptor (LDLR) gene (>85% of cases; >2000 mutations classified into receptor synthesis, transport, binding, internalization, or recycling defects). Less common causes include mutations in the Apolipoprotein B gene (APOB) that impair Apo B-100 binding to LDLR, or gain-of-function mutations in PCSK9 (which accelerates lysosomal destruction of LDLR).
• Laboratory Profile: Profound elevation of Total Cholesterol (300 to 500 mg/dL in heterozygotes; 600 to 1200 mg/dL in homozygotes); calculated and direct LDL-C is severely elevated; Triglycerides are normal. Serum is completely clear with a pronounced orange-yellow tint from dissolved carotenoids.
• Clinical Presentation: Pathognomonic tendon xanthomas (firm, painless nodular deposits of cholesteryl esters, most commonly in the Achilles tendon and extensor tendons of the hands), xanthelasma palpebrarum (yellowish plaques on the inner canthi of the eyelids), and premature corneal arcus (arcus senilis) before age 45.
• Cardiovascular Risk: Extreme, aggressive premature coronary artery disease (CAD). Untreated heterozygotes develop myocardial infarction in their 30s to 40s (males) or 40s to 50s (females). Homozygous FH patients develop severe coronary atherosclerosis and calcific aortic stenosis during childhood, frequently experiencing fatal myocardial infarctions before age 20.
• Management: High-intensity statins, ezetimibe (inhibits NPC1L1 intestinal cholesterol absorption), PCSK9 monoclonal antibodies (evolocumab, alirocumab), and bi-weekly LDL apheresis for homozygotes.

Type IIb: Familial Combined Hyperlipidemia (FCH)

• Molecular Defect: Polygenic / multifactorial etiology. The primary hepatic defect is overproduction of Apolipoprotein B-100 and VLDL secretion, combined with delayed clearance of LDL.
• Laboratory Profile: Elevation of both Total Cholesterol and Triglycerides (both typically 250–500 mg/dL); LDL and VLDL are both elevated. Serum is clear to slightly hazy/opalescent, with no floating cream layer.
• Clinical Presentation: Prevalent in approximately 1 in 200 adults and accounts for 10% to 20% of patients presenting with premature CAD. Tendon xanthomas are typically absent, but patients frequently display metabolic syndrome, insulin resistance, and visceral adiposity.

Type III: Familial Dysbetalipoproteinemia (Broad Beta Disease)

• Molecular Defect: Autosomal recessive inheritance of the homozygous Apolipoprotein E2 allele (APO-E2/E2 genotype). Human Apo E has three major isoforms (E2, E3, E4). Wild-type Apo E3 and Apo E4 bind normally to the LDL receptor and LRP. Apo E2 carries an Arg158Cys substitution that reduces its receptor-binding affinity to <2% of normal, crippling the clearance of chylomicron remnants and IDL. Although ~1% of the population is homozygous E2/E2, overt clinical Type III requires a "second hit" (e.g., obesity, type 2 diabetes, hypothyroidism, or alcohol abuse).
• Laboratory Profile: Equimolar elevation of Total Cholesterol and Triglycerides (a roughly 1:1 mass ratio, with both TC and TG typically between 300 and 600 mg/dL). On agarose gel electrophoresis, an abnormal, pathognomonic broad-beta band spans continuously across the $\beta$ and pre-$\beta$ regions (representing cholesterol-enriched "$\beta$-VLDL"). Serum is turbid or hazy.
• Clinical Presentation: Pathognomonic palmar xanthomas (xanthoma striatum palmare): distinctive planar, orange-yellow lipid streaks along the palmar and digital creases. Patients also exhibit tuberoeruptive xanthomas (coalescing, inflamed nodular lesions on the elbows and knees).
• Cardiovascular Risk: High incidence of severe premature peripheral vascular disease (intermittent claudication) and premature coronary artery disease.

Type IV: Familial Hypertriglyceridemia

• Molecular Defect: Autosomal dominant defect involving hepatic overproduction of VLDL triglycerides or impaired peripheral VLDL catabolism. Highly sensitive to secondary exacerbating factors: high-carbohydrate diets, alcohol, obesity, and exogenous estrogen.
• Laboratory Profile: Moderate to severe elevation of Triglycerides (200 to 800 mg/dL); Total Cholesterol is normal or borderline elevated. Overnight standing plasma displays uniform opalescent or milky turbidity throughout with NO floating cream layer.
• Clinical Presentation: Associated with metabolic syndrome, hepatic steatosis (NAFLD), and elevated cardiovascular risk. If triglycerides surpass 1000 mg/dL, patients are at risk for acute pancreatitis.

Type V: Mixed Hyperlipidemia

• Molecular Defect: Complex multigenic disorder characterized by concurrent VLDL overproduction and saturated chylomicron clearance mechanisms, often triggered by unmanaged type 2 diabetes, heavy alcohol use, or nephrotic syndrome.
• Laboratory Profile: Severe hypertriglyceridemia (>1000 to 3000+ mg/dL) and elevated Total Cholesterol. Standing plasma test displays a creamy floating surface layer over a turbid, milky infranatant.
• Clinical Presentation: Acute pancreatitis risk is high; eruptive xanthomas, lipemia retinalis, and hepatosplenomegaly are common.

---

Genetic Hypolipoproteinemias

+-------------------------------------------------------------------------------------------------------------+
|                                        Major Genetic Hypolipoproteinemias                                   |
+-------------------------------------------------------------------------------------------------------------+
| Disorder               | Gene / Defect             | Laboratory Findings          | Hallmark Clinical Signs  |
+------------------------+---------------------------+------------------------------+--------------------------+
| Abetalipoproteinemia   | *MTTP* (4q23) mutation;   | Total absence of Apo B;      | Acanthocytes (>50% RBCs);|
| (Bassen-Kornzweig)     | Defective lipid loading   | LDL-C undetectable;          | Severe fat malabsorption;|
|                        | onto Apo B in ER          | TC < 30-50 mg/dL, TG ~0      | Ataxia; Retinitis pigmentosa
+------------------------+---------------------------+------------------------------+--------------------------+
| Hypobetalipoproteinemia| *APOB* gene mutations     | Low LDL-C (20-50 mg/dL);     | Usually asymptomatic;    |
|                        | producing truncated Apo B | Low Apo B; Low TC            | Longevity; Reduced CAD   |
+------------------------+---------------------------+------------------------------+--------------------------+
| Tangier Disease        | *ABCA1* (9q31) mutation;  | Near-absence of HDL-C        | Large, orange-yellow     |
| (Familial Alpha-       | Failure of cellular free  | (<5 mg/dL); Low Apo A-I;     | tonsils; Hepatosplenomegaly;
| Lipoprotein Deficiency)| cholesterol efflux        | Low TC; Mild high TG         | Neuropathy; Premature CAD|
+-------------------------------------------------------------------------------------------------------------+

1. Abetalipoproteinemia (Bassen-Kornzweig Syndrome)

• Molecular Genetics: Autosomal recessive mutation in the microsomal triglyceride transfer protein (MTTP) gene on chromosome 4q23. MTTP is an essential molecular chaperone in the endoplasmic reticulum of enterocytes and hepatocytes that transfers neutral lipids onto nascent Apo B polypeptides.
• Pathophysiology: Enterocytes cannot synthesize chylomicrons, and hepatocytes cannot synthesize VLDL. Consequently, all Apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, IDL, and LDL) are completely absent from circulation.
• Laboratory Findings: Serum Total Cholesterol is extremely low (<30 to 50 mg/dL); Triglycerides are near undetectable (<10–20 mg/dL); LDL-C and Apo B are zero.
• Peripheral Blood Smear: Acanthocytosis: over 50% of circulating erythrocytes display irregular, thorny, spike-like projections ("spur cells") caused by an altered erythrocyte membrane lipid ratio (increased sphingomyelin-to-phosphatidylcholine ratio).
• Clinical Manifestations: Severe intestinal fat malabsorption, chronic steatorrhea, failure to thrive in infancy, and profound deficiency of fat-soluble vitamins (A, D, E, K). Deficiency of Vitamin E causes progressive spinocerebellar ataxia, peripheral neuropathy, loss of deep tendon reflexes, and atypical retinitis pigmentosa leading to blindness.

2. Tangier Disease (Familial Alpha-Lipoprotein Deficiency)

• Molecular Genetics: Autosomal recessive mutations in the ATP-Binding Cassette Transporter A1 (ABCA1) gene on chromosome 9q31.
• Pathophysiology: ABCA1 mediates the active efflux of cellular free cholesterol and phospholipids to lipid-poor Apo A-I to form nascent HDL. Without functional ABCA1, lipid-poor Apo A-I cannot acquire lipids and is rapidly filtered and degraded by the renal proximal tubules. Reverse cholesterol transport is halted, causing cellular free cholesterol to accumulate in reticuloendothelial macrophages throughout the body, where it is esterified and trapped.
• Laboratory Findings: Virtually undetectable HDL-C (<5 mg/dL); profoundly depressed Apolipoprotein A-I (<10 mg/dL); low Total Cholesterol (50–100 mg/dL); mild hypertriglyceridemia.
• Pathognomonic Clinical Sign: Strikingly enlarged, lobulated, yellow-orange or orange-gray tonsils and adenoids caused by massive deposition of cholesteryl esters and carotenoids in tissue macrophages. Patients also display hepatosplenomegaly, generalized lymphadenopathy, relapsing peripheral neuropathy (syringomyelia-like dissociated sensory loss), corneal opacities, and premature coronary artery disease.

---

Apolipoproteins as Clinical Biomarkers

+-------------------------------------------------------------------------------------------------------------+
|                                 Apolipoproteins as Diagnostic Biomarkers                                    |
+-------------------------------------------------------------------------------------------------------------+
| Biomarker              | Physiological Significance               | Clinical Utility & Cutoffs              |
+------------------------+------------------------------------------+-----------------------------------------+
| Apolipoprotein A-I     | Major structural protein of HDL (~70%);  | Direct measure of anti-atherogenic      |
| (Apo A-I)              | Activates LCAT; mediates ABCA1 efflux    | HDL particle count; inversely related   |
|                        |                                          | to CAD (Normal: 110-180 mg/dL)          |
+------------------------+------------------------------------------+-----------------------------------------+
| Apolipoprotein B-100   | Structural protein of LDL, VLDL, IDL,    | Direct 1:1 stoichiometric enumeration of|
| (Apo B-100)            | and Lp(a); EXACTLY ONE molecule per      | total circulating atherogenic particles.|
|                        | atherogenic particle                     | Target: <80 mg/dL (high risk: <65 mg/dL)|
+------------------------+------------------------------------------+-----------------------------------------+
| Apo B / Apo A-I Ratio  | Ratio of total atherogenic particles to  | Powerful global predictor of MI risk    |
|                        | reverse cholesterol transport capacity   | (INTERHEART study). Cutoff: >0.90 male, |
|                        |                                          | >0.80 female indicates high risk        |
+-------------------------------------------------------------------------------------------------------------+

Clinical Superiority of Apo B-100 over LDL-C (Discordance)

Because LDL particles vary considerably in their core cholesterol payload, patients with metabolic syndrome, insulin resistance, type 2 diabetes, or elevated triglycerides predominantly produce small, dense LDL particles. These individuals frequently present with a deceptively "normal" calculated LDL-C (e.g., 90 mg/dL) while carrying a dangerously high Apo B-100 particle count (e.g., 125 mg/dL)—a phenomenon termed LDL-C / Apo B discordance. Because every atherogenic particle carries exactly one molecule of Apo B-100, Apo B-100 directly enumerates atherogenic particle burden and is a superior predictor of cardiovascular events.

---

Lipoprotein(a) [Lp(a)]

Lipoprotein(a) is an LDL-like particle consisting of a core of cholesteryl esters and triglycerides encircled by Apo B-100, which is covalently linked via a single disulfide bond to a unique, highly polymorphic glycoprotein: Apolipoprotein(a) [Apo(a)].

                    ┌──────────────────────────────────────────────┐
                    │            Lipoprotein(a) Particle           │
                    └──────────────────────┬───────────────────────┘
                                           │
                   ┌───────────────────────┴───────────────────────┐
                   ▼                                               ▼
        [ Standard LDL Core ]                            [ Apolipoprotein(a) ]
     Apo B-100 + Cholesteryl Esters              Homologous to Plasminogen:
                   │                             - Multiple Kringle IV repeats
                   │                             - Single Kringle V domain
                   │                             - Inactive protease domain
                   └────────── S ─ S ────────────┘
                        (Covalent Disulfide Bond)
                                   │
         ┌─────────────────────────┴─────────────────────────┐
         ▼                                                   ▼
   [ Proatherogenic Effects ]                          [ Prothrombotic Effects ]
   - Intimal proteoglycan binding                     - Competes with plasminogen for fibrin
   - Carries oxidized phospholipids (OxPL)            - Inhibits tPA-mediated fibrinolysis
   - Promotes calcific aortic stenosis                - Enhances microvascular thrombosis

Dual Pathogenic Mechanisms: Atherogenic & Thrombogenic

1. Thrombogenic / Antifibrinolytic Mechanism: Apo(a) exhibits intense structural homology to human plasminogen. Plasminogen contains five homologous "kringle" domains (KI to KV) and a catalytic serine protease domain. Apo(a) contains multiple tandem copies of kringle IV (K-IV), one copy of kringle V, and an inactive pseudoprotease domain. Because of this structural mimicry, Lp(a) competitively inhibits plasminogen binding to fibrin, endothelial surfaces, and annexin A2. This impairs tissue plasminogen activator (tPA)-mediated fibrinolysis, preventing clot dissolution and promoting microvascular thrombosis at sites of plaque rupture.
2. Atherogenic & Calcific Mechanisms: Lp(a) penetrates the endothelial barrier, binds avidly to subendothelial proteoglycans, and delivers pro-inflammatory oxidized phospholipids (OxPL) that promote macrophage foam cell formation. Furthermore, Lp(a) drives osteogenic differentiation of valvular interstitial cells, serving as the primary genetic cause of calcific aortic valve stenosis.

Genetics and Clinical Testing

• Genetic Determination: Plasma Lp(a) concentrations are >90% genetically determined by variation at the LPA gene locus (chromosome 6q26-27), primarily dictated by the number of KIV-2 copy repeats (inversely related: smaller isoforms produce higher circulating levels).
• Therapeutic Resistance: Circulating Lp(a) levels remain remarkably constant across a patient's lifespan and are unresponsive to diet, exercise, and standard statin therapy (statins often cause a modest 10% to 20% rise). Novel RNA therapeutics (antisense oligonucleotides and siRNAs targeting LPA mRNA) lower Lp(a) by >80% to 95% in clinical trials.
• Risk Threshold: Concentrations >50 mg/dL (or >125 nmol/L) denote significantly elevated cardiovascular risk. Current guidelines recommend measuring Lp(a) at least once in a lifetime in all adults to identify high-risk inherited cardiovascular disease.

---

Emerging and Established Cardiac Biomarkers

1. High-Sensitivity C-Reactive Protein (hs-CRP)

C-reactive protein is an ancient, 118-kDa pentameric acute-phase reactant synthesized by hepatocytes under transcriptional stimulation by pro-inflammatory cytokines, predominantly Interleukin-6 (IL-6).

• High-Sensitivity vs. Standard CRP: Standard CRP assays detect gross elevations (10 to 500 mg/L) to diagnose acute bacterial infections or autoimmune flares. High-sensitivity CRP (hs-CRP) employs latex-enhanced immunonephelometry to quantify low-grade, chronic subclinical vascular inflammation in the range of 0.1 to 10.0 mg/L.
• CDC / AHA Cardiovascular Risk Categories:
  • Low Risk: < 1.0 mg/L
  • Average / Moderate Risk: 1.0 to 3.0 mg/L
  • High Risk: > 3.0 mg/L
• Critical Pre-Analytical / Clinical Caveat: If hs-CRP is > 10.0 mg/L, it reflects acute, clinically overt systemic inflammation (e.g., occult bacterial/viral infection, trauma, arthritis flare, or recent surgery) rather than basal vascular atherogenic risk. The test is clinically invalid for cardiovascular risk assessment at levels >10 mg/L. The technologist must note the presence of acute inflammation, and testing must be repeated 2 to 3 weeks after complete resolution of the acute illness.

2. Natriuretic Peptides: BNP and NT-proBNP

Synthesized by ventricular cardiomyocytes in response to increased ventricular wall tension, diastolic stretch, and intravascular volume overload. Ventricular myocytes synthesize a 134-amino-acid pre-proBNP precursor, cleaved to proBNP (108 amino acids), which is proteolytically processed into two circulating fragments:

                                [ Ventricular Cardiomyocyte Stretch ]
                                                  │
                                                  ▼
                                     [ Pre-proBNP (134 aa) ]
                                                  │
                                                  ▼
                                        [ proBNP (108 aa) ]
                                                  │
                         Cleaved by Furin / Corin │ in Equimolar Ratio
                                 ┌────────────────┴────────────────┐
                                 ▼                                 ▼
                     [ B-type Natriuretic Peptide ]    [ N-Terminal proBNP ]
                     [      BNP (32 aa)          ]    [   NT-proBNP (76 aa) ]
                     ├───────────────────────────┤    ├─────────────────────┤
                     │ Active vasodilator hormone│    │ Biologically INACTIVE│
                     │ Stimulates cGMP via NPR-A │    │ No receptor action  │
                     │ Natriuresis, diuresis     │    │ Eliminated RENALLY  │
                     │ Short half-life (~20 min) │    │ Long half-life (~90m│
                     │ Cleared by NEPRILYSIN     │    │ NOT a substrate for │
                     │ & NPR-C receptor          │    │ neprilysin          │
                     └───────────────────────────┘    └─────────────────────┘

Diagnostic Utility in Heart Failure

• Emergency Triage: Distinguishes acute cardiogenic dyspnea (congestive heart failure / CHF) from non-cardiac pulmonary causes (COPD exacerbation, asthma, pneumonia). Both markers display a negative predictive value >98%:
  • BNP < 100 pg/mL or NT-proBNP < 300 pg/mL effectively rules out acute decompensated heart failure.
• Renal Influence: NT-proBNP relies strictly on renal clearance; reduced GFR (<60 mL/min) elevates baseline NT-proBNP, requiring age-stratified diagnostic cutoffs (e.g., 450 pg/mL for <50 years; 900 pg/mL for 50–75 years; 1800 pg/mL for >75 years).
• Drug Interaction with Neprilysin Inhibitors (ARNIs): Sacubitril/valsartan (Entresto) inhibits neprilysin, the enzyme responsible for degrading active BNP. Consequently, patients taking sacubitril exhibit pharmacologically elevated BNP levels that do not reflect heart failure exacerbation. Because NT-proBNP is not cleared by neprilysin, NT-proBNP MUST be used to monitor heart failure status in patients on ARNI therapy.